GENE ONLINE|News &
Innovent Announces Gastric Cancer Trial Win for Tyvyt, Reveals Plans for Another China Approval
Earlier today, Innovent announced positive outcomes from a gastric cancer trial that evaluated Tyvyt (sintilimab injection) in combination with chemotherapy. Interim analysis shows that the combo therapy met the primary endpoint of overall survival in patients.
Approved originally for treating relapsed or refractory classical Hodgkin’s lymphoma in China, Tyvyt had recently bagged its third NMPA approval. The immunotherapy, a fully human IgG4 anti-PD-1 monoclonal antibody, was developed by Innovent in collaboration with Eli Lilly.
Approved originally for treating relapsed or refractory classical Hodgkin’s lymphoma in China, Tyvyt had recently bagged its third NMPA approval. The immunotherapy, a fully human IgG4 anti-PD-1 monoclonal antibody, was developed by Innovent in collaboration with Eli Lilly.
GO Prime with only $1.49 now
LATEST
BD and A*STAR collaborate to Advance Ultra-High Dimensional Analysis in Flow Cytometry for Immunology Research
2023-03-28
Amway Applauded by Frost & Sullivan for Capitalizing on Innovative Competitive Strategies to Drive Differentiation in Its Home Water Treatment Solution in APAC
2023-03-28
